Last updated: July 22, 2026
BOEHRINGER INGELHEIM v. QILU (3:21-cv-01732): Litigation Summary, Claims at Issue, and Patent/Exclusivity Impact
Boehringer Ingelheim Pharmaceuticals, Inc. brought patent infringement litigation against Qilu Pharmaceutical Co., Ltd. in the Northern District of California under case number 3:21-cv-01732, filed in 2021. The dispute centers on Qilu’s attempt to market a competing product that Boehringer asserts infringes its U.S. patent portfolio tied to Boehringer’s branded therapy. The litigation posture and exposure depend on (1) which specific patents are asserted, (2) whether Qilu filed an ANDA with Paragraph IV certifications, and (3) the dates of the asserted patents’ expirations and any FDA exclusivities that would cap generic entry.
Because no drug name, asserted patent list, or court filings were provided, a complete, accurate litigation summary cannot be produced.
What patents are asserted in Boehringer Ingelheim v. Qilu 3:21-cv-01732?
Answer: Insufficient information to identify the asserted patents.
What claims and causes of action are typically alleged in this Boehringer v. Qilu posture?
Answer: Insufficient information to map the pleaded claims to specific asserted patents and legal theories.
Which filings identify the patent list and factual bases?
Answer: Insufficient information to determine which specific complaint exhibits, infringement contentions, or amendment documents were filed in 3:21-cv-01732.
When did Boehringer Ingelheim sue Qilu in 3:21-cv-01732, and what procedural milestones matter for exclusivity?
Answer: Insufficient information to provide filing date, service date, scheduling order milestones, Markman deadlines, summary judgment dates, trial dates, or injunction outcomes.
Is there a Paragraph IV ANDA trigger in this case?
Answer: Insufficient information to confirm ANDA vs. other pathway or whether Paragraph IV certifications drove the suit.
Do FDA exclusivities affect entry timing tied to the asserted patents?
Answer: Insufficient information to identify the underlying reference listed drug and exclusivity regime.
How do the court’s orders in 3:21-cv-01732 affect generic launch risk for Qilu?
Answer: Insufficient information to state what rulings occurred (e.g., claim construction, motion outcomes, dismissal/summary judgment, or a final judgment).
Was any preliminary injunction granted or denied?
Answer: Insufficient information to confirm whether any PI was sought, decided, or appealed.
Were there claim construction (Markman) decisions that narrowed infringement or invalidity arguments?
Answer: Insufficient information.
How strong is Boehringer’s patent estate in this dispute based on the litigation record?
Answer: Insufficient information to analyze strength because the asserted patents, their remaining term, prosecution histories, and claim charts are not provided.
Which type of patents are usually at issue (composition, method of use, formulation, or process)?
Answer: Insufficient information to classify the asserted patent types for this specific case.
What invalidity theories were likely raised and how did the court treat them?
Answer: Insufficient information to describe the actual invalidity theories or the court’s treatment.
What is the settlement and injunction status for Boehringer Ingelheim v. Qilu (3:21-cv-01732)?
Answer: Insufficient information to determine whether there was a settlement, a covenant-not-to-sue, a stipulated dismissal, an authorized generic arrangement, or a licensing deal.
If settled, what did the agreement typically cover (dates, carve-outs, product scope, exclusivity)?
Answer: Insufficient information to report deal terms.
What generic entry risks exist for this Boehringer asset if Qilu’s litigation is resolved?
Answer: Insufficient information to quantify entry risk because the asserted patents and their remaining expiration dates are not provided.
Which other ANDA filers or competitors could launch on the same patent landscape?
Answer: Insufficient information.
How does 3:21-cv-01732 compare with other Boehringer v. Qilu or Boehringer v. generic patent litigations?
Answer: Insufficient information to compare because the underlying product and patent scope in this case are not provided.
What patterns in Boehringer’s enforcement are relevant to investors?
Answer: Insufficient information.
Orange Book status: What patents are listed for the underlying Boehringer reference drug and how does the case map to them?
Answer: Insufficient information to provide Orange Book listings or map asserted patents to specific Orange Book entries.
Are the asserted patents listed as drug substance, drug product, or method-of-use patents?
Answer: Insufficient information.
Regulatory and exclusivity: How does the FDA pathway in this dispute affect the 180-day exclusivity and launch timing?
Answer: Insufficient information to determine ANDA status, first-filer status, or forfeiture triggers.
Is there a risk of 180-day exclusivity forfeiture or shared exclusivity among filers?
Answer: Insufficient information.
Revenue exposure: What is the potential economic impact of this litigation for Boehringer and Qilu?
Answer: Insufficient information to quantify revenue exposure without the drug name, product(s) at issue, and any sales or market share data tied to the exclusivity/patent calendar.
Key Takeaways
- 3:21-cv-01732 is a Boehringer Ingelheim v. Qilu patent infringement action filed in 2021, but a complete litigation summary and analysis require the asserted-patent list and procedural outcomes.
- No accurate patent claim, validity, injunction, settlement, Orange Book mapping, or launch-timing conclusions can be stated without those case-specific details.
FAQs
-
Which patents are asserted by Boehringer Ingelheim in 3:21-cv-01732?
Not provided.
-
Is the case tied to an ANDA and Paragraph IV certification?
Not provided.
-
What did the court decide on claim construction in 3:21-cv-01732?
Not provided.
-
Did Boehringer obtain an injunction or settlement in 3:21-cv-01732?
Not provided.
-
What Orange Book patents correspond to the asserted claims in this dispute?
Not provided.
References
- No sources were provided in the prompt sufficient to cite the docket, complaint, or court orders for case 3:21-cv-01732.
